Prenatal inhibition of vasoactive intestinal peptide and brain excitotoxic lesions in the newborn mouse pup;Inhibition prenatale du peptide vasoactif intestinal et lesions cerebrales excitotoxiques du souriceau nouveau-ne

Archives de Pediatrie

Volumn 6, Issue 1, 1999, Pages 67-74

  Lamboley, G ^a   Evrard, P ^a   Gressens, P ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Astrocytes; Cerebral palsy; Leukomalacia, periventricular; Neuroprotective agents

Indexed keywords

IBOTENIC ACID; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; DRUG DERIVATIVE; EXCITATORY AMINO ACID; GLUTAMIC ACID; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CEREBRAL PALSY; LEUKOMALACIA; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NEWBORN; NONHUMAN; PRENATAL DEVELOPMENT; WHITE MATTER; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENCEPHALOMALACIA; FEMALE; HUMAN; MOUSE STRAIN; PATHOLOGY; PHYSIOLOGY; PREGNANCY;

ANIMALS; ANIMALS, NEWBORN; CEREBRAL PALSY; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EMBRYONIC AND FETAL DEVELOPMENT; EXCITATORY AMINO ACIDS; FEMALE; GLUTAMIC ACID; HUMANS; IBOTENIC ACID; INFANT, NEWBORN; LEUKOMALACIA, PERIVENTRICULAR; MICE; MICE, INBRED STRAINS; NEUROPROTECTIVE AGENTS; PREGNANCY; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0032618865     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(99)80077-3     Document Type: Article

References (35)

1. 1 Volpe JJ. Effect of cocaine use on the fetus. N Engl J Med 327 : 399-407
2. 2 Gressens P, Cilio R, Schlogel X, Evrard P. Les mécanismes de la souffrance cérébrale du fœtus et du prématuré. Des espoirs de prévention et de traitement. In : Relier JP, ed. Progrès en néonatologie. Vol 17. Basel: Karger; 1991. p 203-26
3. 3 Evrard P, Miladi N, Bonnier C, Gressens P. Normal and abnormal development of the brain. In: Rapin I, Segalowitz SJ, eds. Handbook of Neurophysiology, vol 6: Child Neuropsychology. Amsterdam: Elsevier Sciences publishers; 1992. p 11-44
4. 4 Nelson KB, Ellenberg JH. Antecedents of cerebral palsy. Multivariate analysis of risk. N Eng J Med 1986 ; 315 : 81-6
5. 5 Evrard P, Marret S, Gressens P. Environmental determinants of brain development, with a special emphasis on the excitotoxic cascade at the consecutive developmental steps. In: Rating D, ed. Aktuelle bv Neuropädiatrie. Wehr: Ciba-Geigy Verlag ; 1995. p 22-33
6. 6 Evrard P, Marret S, Gressens P. Environmental and genetic determinants of neuronal migration and postmigratory survival. Acta Paediatr 1997 ; Suppl 422 : 20-6
7. 7 Volpe JJ. Neurology of the Newborn. 3rd ed. Philadelphia: WB Saunders; 1995
8. 8 Murphy DJ, Sellers S, Mackenzie IZ, Yudkin PL, Johnson AM. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet 1995 ; 346 : 1449-54
9. 9 Murphy DJ, Hope PL, Johnson A. Neonatal risk factors for cerebral palsy in very preterm babies: case-control study. Br Med J 1997 ; 314 : 404-8
10. 10 Zupan V, Gonzales P, Lacaze-Masmonteil T, Boithias C, d'Allest AM, Dehan M et al. Periventricular leukomalacia: risk factors revisited. Dev Child Neurol 1996. 38 : 1061-7
11. 11 Gressens P, Marret S, Evrard P. La neuroprotection du cerveau du nouveau-né. In : Relier JP, ed. Progrès en néonatologie. Vol 17. Paris : Karger ; 1997. p 40-61
12. 12 Marret S, Zupan V, Gressens P, Lagercrantz H, Evrard P. Les leucomalacies périventriculaires. I. Aspects histologiques et étiopathogéniques. Arch Pédiatr 1998 ; 5 : 525-37
13. 13 Marret S, Zupan V, Gressens P, Lagercrabtz H, Evrard P. Les leucomalacies périventriculaires. II. Diagnostic, séquelles et neuroprotection. Arch Pédiatr 1998 ; 5 : 538-45
14. 14 McDonald JW, Johnson MV. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Rev 1990 ; 15 : 41-70
15. 15 Marret S, Mukendi R, Gadisseux JF, Gressens P, Evrard P. Effects of ibotenate on brain development: an excitotoxic mouse model of microgyria and post hypoxic-like lesions. J Neuropathol Exp Neurol 1995 ; 54 : 358-70
16. 16 Marret S, Gressens P, Evrard P. Arrest of neuronal migration by excitatory amino acids in hamster developing brain. Proc Natl Acad Sci USA 1996 ; 63 : 15463-8
17. 17 Gressens P, Marret S, Evrard P. Developmental spectrum of the excitotoxic cascade induced by ibotenate: a model of hypoxic insults in fetuses and neonates. Neuropathol Applied Neurobiol 1996 ; 22 : 498-502
18. 18 Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, Fridkin M et al. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J Clin Invest 1997 ; 100 : 390-7
19. 19 Marret S, Gadisseux JF, Gressens P, Evrard P. Prevention by magnesium of excitotoxic neuronal death in developing brain. An animal model for the clinical intervention studies. Dev Med Child Neurol 1995 ; 37 : 473-84
20. 20 Bac P, Maurois P, Dupont C, Pages N, Stables JP, Gressens P et al. Magnesium deficiency-dependent audiogenic seizures (MDDAS) in adult mice: a nutritional model for discriminatory screening of anticonvulsivant drugs and original assessment of neuroprotection properties. J Neurosci 1998 ; 18 : 4363-73
21. o synthase inhibitor protect the developing mouse brain against neonatal excitotoxic lesions. Pediatr Res 1999 (à paraître)
22. 22 Gressens P. Le peptide vasoactif intestinal : un nouveau facteur neurotrophique. Arch Pédiatr 1998 ; 5 : 654-60
23. 23 Brenneman DE, Hill JM, Gressens P, Gozes I. Neurotrophic action of VIP: from CNS ontogeny to therapeutic strategy. In: Said SS, ed. Pro-Inflammatory and Anti-Inflammatory Peptides. New York: M Dekker, Inc; 1997
24. 24 Zupan V, Hill JM, Brenneman DE, Gozes I, Fridkin M, Robberecht P et al. Involvment of PACAP II VIP2 receptor in mouse neocortical astrocytogenesis. J Neurochem 1998 ; 70 : 2165-73
25. 25 Gressens P, Richelme C, Kadhim HJ, Gadisseux JF, Evrard P. The germinative zone produces the most cortical astrocytes after neuronal migration in the developing mammalian brain. Biol Neonate 1992 ; 61 : 4-24
26. 26 Jacobson M. Developmental Neurobiology. 3rd ed. New York: Plenum Press, 1991. p 776
27. 27 McMorris FA, Smith TM, De Salvo S, Furlanetto RW. Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci USA 1986 ; 83 : 822-6
28. 28 Pettman B, Weibl M, Sensenbrenner M, Labourdette G. Purification of two astroglial growth factors from bovine brain. FEBS Lett 1985 ; 189 : 102-8
29. 29 Brenneman DE, Gozes I. A fentomolar-acting neuropeptide. J Clin Invest 1996 ; 97 : 2299-307
30. 30 Gozes I, Meltzer E, Rurinraut S, Brenneman DE. Vasoactive intestinal peptide potentiates sexual behaviour: inhibition by a novel antagonist. Endocrinology 1989 ; 125 : 2945-9
31. 31 Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, Fridkin M et al. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J Pharmacol Exp Ther 1991 ; 257 : 959-66
32. 32 Gozes Y, Brenneman DE, Fridkin M, Asofsky R, Gozes I. A VIP antagonist distinguishes VIP receptors in spinal cord and lymphocytes. Brain Res 1991 ; 540 : 319-21
33. 33 Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci 1997 ; 3 : 132-9
34. 34 Gressens P, Hill JM, Gozes I, Fridkin M, Brenneman DE. Growth factor function of vasoactive intestinal peptide in whole mouse cultured embryos. Nature 1993 ; 362 : 155-8
35. 35 Gressens P, Hill JM, Paindaveine B, Gozes I, Fridkin M, Brenneman DE. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in primitive neuroepithelium of the mouse. J Clin Invest 1994 ; 94 : 2020-4